US2018028581A1PendingUtilityA1
Bacterial composition and its use
Est. expiryDec 5, 2022(expired)· nominal 20-yr term from priority
A61P 37/04A61P 37/02A61P 37/08A61P 37/00A61P 29/00A61P 1/00A61K 35/745C12N 1/20A61K 35/747C12R 1/225C12R 1/01C12R 1/23C12R 1/25C12R 2001/23C12R 2001/25C12R 2001/225C12R 2001/01C12N 1/205
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.
Claims
exact text as granted — not AI-modified1 . A bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
2 . The bacterial composition according to claim 1 , wherein the strains is selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, and Bifidobacterium lactis PTA-4802.
3 . The bacterial composition according to claim 1 wherein the strain is Lactobacillus acidophilus PTA-4797.
4 . The bacterial composition according to claim 1 wherein the strain is Lactobacillus plantarum PTA-4799.
5 . The bacterial composition according to claim 1 wherein the strain is Bifidobacterium lactis PTA-4802.
6 . The bacterial composition according to claim 1 comprising at least 2 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
7 . The bacterial composition according to claim 1 comprising at least 3 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
8 . The bacterial composition according to claim 1 comprising a blend of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium lactis PTA-4802 and Bifidobacterium bifidum PTA-4801.
9 . The bacterial composition according to claim 1 , characterized in that it comprises from 10 6 to 10 11 CFU of bacteria/g of composition.
10 . The bacterial composition according to claim 1 , characterized in that it comprises from 10 8 to 10 11 CFU of bacteria/g of composition.
11 - 14 . (canceled)
15 . An immunomodulation method comprising the step of using at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
16 . A food, dietary supplement or pharmaceutical composition comprising the composition according to claim 1 .
17 . A composition according to claim 16 , characterized in that it is a dairy product.
18 . A composition according to claim 16 , characterized in that it is an infant formula.
19 . A composition according to claim 16 , wherein the composition has immunomodulation properties.
20 . A pharmaceutical composition comprising the composition according to claim 1 .
21 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.